Severe Malaria in Remote Areas- Closing the Evidence Gap
Key facts
- Who runs it
- Tropical Diseases Research Centre, Zambia
- Where
- Congo - Kinshasa and Zambia2 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Enrolling by invitation
- People taking part
- 2,016 people, planned
- Started
- 10 Mar 2024
- Expected to end
- Apr 2027
- Type of study
- Observational
- Treatments tested
- Treatment of severe malaria with either RAS + ACT or RAS + injectable artesunate + ACT will each achieve the clinically acceptable cure rate of 97% ± 5% in remote areas
- Record updated
- 27 January 2026
Who can take part
- Age
- 6 months to 5 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- From a village without other research interventions
- Children aged from 6 months to ≤5 years that present at the health system and are either; with fever (or history of fever within 2 days) and have a positive mRDT test plus at least one of the following danger signs for malaria (as per standardized national iCCM guidelines):; convulsions; inability to drink, eat, or suck; vomiting all liquids and solids; altered consciousness/coma; lethargy; chest in-drawing Inclusion for uncomplicated malaria
- Children aged from 6 months to ≤5 years; with fever (or history of fever within 2 days) with no danger signs for malaria (as per the standardized national Integrated Management of Childhood Illnesses guidelines) with a positive mRDT for Plasmodium falciparum histidine-rich protein; Inclusion for severe non-malaria
- From a village without other research interventions
- Children aged from 6 months to ≤5 years that present at the health system and are either; with fever (or history of fever within 2 days) and have a negative mRDT test plus at least one of the following danger signs as per standardized national iCCM guidelines:; convulsions; inability to drink, eat, or suck; vomiting all liquids and solids; altered consciousness/coma; lethargy; chest in-drawing
- For participants in sentinel sites, a written informed consent will be provided by the patient's parent or guardian to take filter paper blood samples and to participate in interviews (questionnaires and IDI) at enrolment, day 14 and day 28 (to assess malaria recurrence and look for markers of resistance). If the parent or guardian is unable to write, thumb print witnessed consent is permitted. The informed consent shall be administered by the CHWs. Willingness and ability of the patient and the parent or guardian to comply with the treatment policy
Who cannot take part
- Participation in other studies within 30 days before the current study begins and/or during study participation
- Use of any investigational or non-registered product or planned use during the study period
- Inability to comprehend and/or unwillingness to follow the study protocol
- For RAS use: if the child has reacted badly to artesunate in the past (in sites where RAS is administered)
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this observational study is to assess whether the giving of rectal artesunate and a three day course of an Artemisinin based Combination Therapy (ACT) to children aged 6 months and ≤ 5 years with severe malaria when referral is not feasible is non inferior to giving of injectable artesunate and three day course of an ACT. The three primary objectives are:
Read full original descriptionShow less
* To evaluate the 28-day PCR corrected cure rate in children aged 6 months to ≤ 5 years treated with RAS+ACT or RAS+injectable artesunate, assessing whether each treatment achieves the clinically acceptable cure rate of 97% ± 5%. * To evaluate feasibility of provision of rapid treatment of severe malaria with rectal artesunate in children 6 months to ≤ 5 years not able to access a referral health facility, by a community health worker or in health facility where there is no injectable artesunate available. * To evaluate the impact of reinforcing the integrated Community Case Management (iCCM) on access to the formal health care system
The study is being done in Nchelenge district in Zambia and Kapolowe district in the Democratic Republic of Congo. It will enrol 1008 children with severe malaria and an equal number of children with simple malaria
The group in the trial
- Two groups i.e rectal artesunate +ACT group while the other is injectable artesunate +ACT group
The group of interest is children aged between 6 months and less than or equal to 5 years with severe malaria. However, we will also enrol children of the same age group with simple malaria and non malaria severe disease to compare their journeys as well
Treatment: Treatment of severe malaria with either RAS + ACT or RAS + injectable artesunate + ACT will each achieve the clinically acceptable cure rate of 97% ± 5% in remote areas
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Severe Malaria Treatment With Rectal Artesunate and Artemisinin-based Combination Therapy in Remote Settings
- Record updated
- 27 January 2026